EA015351B1 - Антагонисты il-17a и il-17f и способы их применения - Google Patents

Info

Publication number

EA015351B1

EA015351B1 EA200800956A EA200800956A EA015351B1 EA 015351 B1 EA015351 B1 EA 015351B1 EA 200800956 A EA200800956 A EA 200800956A EA 200800956 A EA200800956 A EA 200800956A EA 015351 B1 EA015351 B1 EA 015351B1

Authority

EA

Eurasian Patent Office

Prior art keywords

polypeptide

disease

amino acid

sequence

cells

Prior art date

2005-09-28

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 140
• 239000005557 antagonist Substances 0.000 title claims abstract description 48
• 102000013691 Interleukin-17 Human genes 0.000 title abstract description 7
• 108050003558 Interleukin-17 Proteins 0.000 title abstract description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 83
• 201000010099 disease Diseases 0.000 claims abstract description 81
• 230000004054 inflammatory process Effects 0.000 claims abstract description 54
• 230000000694 effects Effects 0.000 claims abstract description 50
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 445
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 404
• 229920001184 polypeptide Polymers 0.000 claims description 389
• 210000004027 cell Anatomy 0.000 claims description 213
• 108090000623 proteins and genes Proteins 0.000 claims description 200
• 102000004169 proteins and genes Human genes 0.000 claims description 103
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 92
• 125000000539 amino acid group Chemical group 0.000 claims description 78
• 102000039446 nucleic acids Human genes 0.000 claims description 70
• 108020004707 nucleic acids Proteins 0.000 claims description 70
• 150000007523 nucleic acids Chemical class 0.000 claims description 70
• 108020004414 DNA Proteins 0.000 claims description 62
• 230000014509 gene expression Effects 0.000 claims description 61
• 206010061218 Inflammation Diseases 0.000 claims description 51
• 108700024394 Exon Proteins 0.000 claims description 41
• 125000003729 nucleotide group Chemical group 0.000 claims description 40
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 40
• 239000002773 nucleotide Substances 0.000 claims description 38
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 33
• 201000004681 Psoriasis Diseases 0.000 claims description 32
• 239000013604 expression vector Substances 0.000 claims description 32
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 29
• 208000006673 asthma Diseases 0.000 claims description 28
• 230000002757 inflammatory effect Effects 0.000 claims description 28
• 208000027866 inflammatory disease Diseases 0.000 claims description 22
• 102000040430 polynucleotide Human genes 0.000 claims description 22
• 108091033319 polynucleotide Proteins 0.000 claims description 22
• 239000002157 polynucleotide Substances 0.000 claims description 22
• 208000015181 infectious disease Diseases 0.000 claims description 21
• 238000013518 transcription Methods 0.000 claims description 20
• 230000035897 transcription Effects 0.000 claims description 20
• 206010003246 arthritis Diseases 0.000 claims description 17
• 230000028993 immune response Effects 0.000 claims description 15
• 230000003993 interaction Effects 0.000 claims description 15
• 208000037487 Endotoxemia Diseases 0.000 claims description 14
• 208000037976 chronic inflammation Diseases 0.000 claims description 14
• 230000000770 proinflammatory effect Effects 0.000 claims description 14
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
• 201000006417 multiple sclerosis Diseases 0.000 claims description 12
• 208000023275 Autoimmune disease Diseases 0.000 claims description 11
• 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 11
• 238000006386 neutralization reaction Methods 0.000 claims description 11
• 241001465754 Metazoa Species 0.000 claims description 10
• 206010040070 Septic Shock Diseases 0.000 claims description 10
• 230000001154 acute effect Effects 0.000 claims description 10
• 230000001684 chronic effect Effects 0.000 claims description 10
• 241000124008 Mammalia Species 0.000 claims description 9
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
• 201000008937 atopic dermatitis Diseases 0.000 claims description 8
• 238000002955 isolation Methods 0.000 claims description 8
• 201000008482 osteoarthritis Diseases 0.000 claims description 8
• 210000002345 respiratory system Anatomy 0.000 claims description 8
• 230000002401 inhibitory effect Effects 0.000 claims description 7
• 208000035473 Communicable disease Diseases 0.000 claims description 6
• 208000011231 Crohn disease Diseases 0.000 claims description 6
• 206010040047 Sepsis Diseases 0.000 claims description 6
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
• 230000002829 reductive effect Effects 0.000 claims description 6
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 201000009961 allergic asthma Diseases 0.000 claims description 4
• 230000007423 decrease Effects 0.000 claims description 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
• 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
• 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• 206010012442 Dermatitis contact Diseases 0.000 claims description 2
• 206010052779 Transplant rejections Diseases 0.000 claims description 2
• 208000010247 contact dermatitis Diseases 0.000 claims description 2
• 208000019693 Lung disease Diseases 0.000 claims 1
• 230000000414 obstructive effect Effects 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 abstract description 85
• 108090000695 Cytokines Proteins 0.000 abstract description 85
• 102100035012 Interleukin-17 receptor C Human genes 0.000 abstract 1
• 101710186068 Interleukin-17 receptor C Proteins 0.000 abstract 1
• 102000005962 receptors Human genes 0.000 description 170
• 108020003175 receptors Proteins 0.000 description 170
• 235000018102 proteins Nutrition 0.000 description 99
• 230000027455 binding Effects 0.000 description 97
• 238000009739 binding Methods 0.000 description 94
• 239000012634 fragment Substances 0.000 description 73
• 235000001014 amino acid Nutrition 0.000 description 68
• 239000003446 ligand Substances 0.000 description 63
• 102000053602 DNA Human genes 0.000 description 61
• 229940024606 amino acid Drugs 0.000 description 53
• 210000001519 tissue Anatomy 0.000 description 50
• 150000001413 amino acids Chemical class 0.000 description 48
• 239000002502 liposome Substances 0.000 description 45
• 108010076504 Protein Sorting Signals Proteins 0.000 description 42
• 102000037865 fusion proteins Human genes 0.000 description 39
• 108020001507 fusion proteins Proteins 0.000 description 39
• 238000004519 manufacturing process Methods 0.000 description 38
• 238000011282 treatment Methods 0.000 description 33
• 210000001744 T-lymphocyte Anatomy 0.000 description 30
• 238000004458 analytical method Methods 0.000 description 29
• 108020004635 Complementary DNA Proteins 0.000 description 28
• 238000006243 chemical reaction Methods 0.000 description 28
• 210000001072 colon Anatomy 0.000 description 28
• 238000010804 cDNA synthesis Methods 0.000 description 26
• 239000002299 complementary DNA Substances 0.000 description 26
• 108020004999 messenger RNA Proteins 0.000 description 26
• 239000013598 vector Substances 0.000 description 26
• 108020004705 Codon Proteins 0.000 description 25
• 241000699666 Mus <mouse, genus> Species 0.000 description 25
• 239000000203 mixture Substances 0.000 description 25
• 229920001223 polyethylene glycol Polymers 0.000 description 25
• 230000003248 secreting effect Effects 0.000 description 25
• 239000002202 Polyethylene glycol Substances 0.000 description 24
• 230000000295 complement effect Effects 0.000 description 24
• 238000006467 substitution reaction Methods 0.000 description 24
• 230000001225 therapeutic effect Effects 0.000 description 24
• 238000005516 engineering process Methods 0.000 description 23
• 230000000890 antigenic effect Effects 0.000 description 22
• 239000003795 chemical substances by application Substances 0.000 description 21
• 230000004927 fusion Effects 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 21
• 229920002477 rna polymer Polymers 0.000 description 21
• 208000024891 symptom Diseases 0.000 description 21
• 239000000427 antigen Substances 0.000 description 20
• 108091007433 antigens Proteins 0.000 description 20
• 102000036639 antigens Human genes 0.000 description 20
• 241000699670 Mus sp. Species 0.000 description 19
• 108091028043 Nucleic acid sequence Proteins 0.000 description 19
• 230000001404 mediated effect Effects 0.000 description 19
• 229920000642 polymer Polymers 0.000 description 19
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 17
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 17
• 238000013459 approach Methods 0.000 description 16
• 238000003776 cleavage reaction Methods 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 239000002158 endotoxin Substances 0.000 description 16
• 230000003834 intracellular effect Effects 0.000 description 16
• 230000001105 regulatory effect Effects 0.000 description 16
• 238000012216 screening Methods 0.000 description 16
• 230000000875 corresponding effect Effects 0.000 description 15
• 108010057085 cytokine receptors Proteins 0.000 description 15
• 102000003675 cytokine receptors Human genes 0.000 description 15
• 230000006378 damage Effects 0.000 description 15
• 229920006008 lipopolysaccharide Polymers 0.000 description 15
• 238000003752 polymerase chain reaction Methods 0.000 description 15
• 230000004913 activation Effects 0.000 description 14
• 230000006870 function Effects 0.000 description 14
• 230000007017 scission Effects 0.000 description 14
• 210000003491 skin Anatomy 0.000 description 14
• 241001529936 Murinae Species 0.000 description 13
• 206010009887 colitis Diseases 0.000 description 13
• 125000005647 linker group Chemical group 0.000 description 13
• 210000002540 macrophage Anatomy 0.000 description 13
• 210000000440 neutrophil Anatomy 0.000 description 13
• 230000037361 pathway Effects 0.000 description 13
• 241000894007 species Species 0.000 description 13
• 230000008859 change Effects 0.000 description 12
• 239000003550 marker Substances 0.000 description 12
• 239000011159 matrix material Substances 0.000 description 12
• 102000008186 Collagen Human genes 0.000 description 11
• 108010035532 Collagen Proteins 0.000 description 11
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
• 229920001436 collagen Polymers 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000018109 developmental process Effects 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 210000004072 lung Anatomy 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 239000007787 solid Substances 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 10
• 108060003951 Immunoglobulin Proteins 0.000 description 10
• 241000700605 Viruses Species 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 229940127121 immunoconjugate Drugs 0.000 description 10
• 102000018358 immunoglobulin Human genes 0.000 description 10
• 150000002632 lipids Chemical class 0.000 description 10
• 210000004379 membrane Anatomy 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 239000000178 monomer Substances 0.000 description 10
• 230000001575 pathological effect Effects 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 238000000746 purification Methods 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 229940124597 therapeutic agent Drugs 0.000 description 10
• 229920003169 water-soluble polymer Polymers 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 229940088598 enzyme Drugs 0.000 description 9
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
• 230000003394 haemopoietic effect Effects 0.000 description 9
• 210000004185 liver Anatomy 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 238000002703 mutagenesis Methods 0.000 description 9
• 231100000350 mutagenesis Toxicity 0.000 description 9
• 230000006320 pegylation Effects 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 241000701447 unidentified baculovirus Species 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 206010028980 Neoplasm Diseases 0.000 description 8
• 239000004372 Polyvinyl alcohol Substances 0.000 description 8
• 230000002391 anti-complement effect Effects 0.000 description 8
• 230000003302 anti-idiotype Effects 0.000 description 8
• 108010008730 anticomplement Proteins 0.000 description 8
• 230000005540 biological transmission Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 239000003937 drug carrier Substances 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 108020001756 ligand binding domains Proteins 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 230000008506 pathogenesis Effects 0.000 description 8
• 229920002451 polyvinyl alcohol Polymers 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 241000196324 Embryophyta Species 0.000 description 7
• 108091034117 Oligonucleotide Proteins 0.000 description 7
• 206010052428 Wound Diseases 0.000 description 7
• 208000027418 Wounds and injury Diseases 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 210000000612 antigen-presenting cell Anatomy 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 210000000845 cartilage Anatomy 0.000 description 7
• 239000008187 granular material Substances 0.000 description 7
• 210000002443 helper t lymphocyte Anatomy 0.000 description 7
• 210000002865 immune cell Anatomy 0.000 description 7
• 230000005764 inhibitory process Effects 0.000 description 7
• 229910052740 iodine Inorganic materials 0.000 description 7
• 210000003734 kidney Anatomy 0.000 description 7
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 7
• 238000010172 mouse model Methods 0.000 description 7
• 239000002245 particle Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 238000000926 separation method Methods 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 230000014616 translation Effects 0.000 description 7
• 238000012384 transportation and delivery Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 102000014914 Carrier Proteins Human genes 0.000 description 6
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 6
• 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 6
• 206010020751 Hypersensitivity Diseases 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
• 102100040247 Tumor necrosis factor Human genes 0.000 description 6
• 208000025865 Ulcer Diseases 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 238000005917 acylation reaction Methods 0.000 description 6
• 238000001042 affinity chromatography Methods 0.000 description 6
• 230000003110 anti-inflammatory effect Effects 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 230000001580 bacterial effect Effects 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 230000036772 blood pressure Effects 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 238000007429 general method Methods 0.000 description 6
• 239000000833 heterodimer Substances 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 230000000977 initiatory effect Effects 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 210000001503 joint Anatomy 0.000 description 6
• 210000003292 kidney cell Anatomy 0.000 description 6
• 239000004005 microsphere Substances 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 230000003472 neutralizing effect Effects 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 238000005932 reductive alkylation reaction Methods 0.000 description 6
• 229920005989 resin Polymers 0.000 description 6
• 239000011347 resin Substances 0.000 description 6
• 230000036303 septic shock Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
• -1 1CAM-1 Proteins 0.000 description 5
• 201000004624 Dermatitis Diseases 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• 108010024636 Glutathione Proteins 0.000 description 5
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
• 208000002193 Pain Diseases 0.000 description 5
• 206010033645 Pancreatitis Diseases 0.000 description 5
• 108010090804 Streptavidin Proteins 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 208000026935 allergic disease Diseases 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 238000004520 electroporation Methods 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 230000008595 infiltration Effects 0.000 description 5
• 238000001764 infiltration Methods 0.000 description 5
• 210000004969 inflammatory cell Anatomy 0.000 description 5
• 230000004968 inflammatory condition Effects 0.000 description 5
• 230000028709 inflammatory response Effects 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229920002521 macromolecule Polymers 0.000 description 5
• 230000036407 pain Effects 0.000 description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 230000035882 stress Effects 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
• 230000002103 transcriptional effect Effects 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
• 101710187798 60S ribosomal protein L23 Proteins 0.000 description 4
• 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 4
• 108090000994 Catalytic RNA Proteins 0.000 description 4
• 206010012735 Diarrhoea Diseases 0.000 description 4
• 208000009386 Experimental Arthritis Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 102000014150 Interferons Human genes 0.000 description 4
• 108010050904 Interferons Proteins 0.000 description 4
• 102220475874 Keratin, type I cytoskeletal 10_L17A_mutation Human genes 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 108700008625 Reporter Genes Proteins 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 230000010933 acylation Effects 0.000 description 4
• 150000001299 aldehydes Chemical class 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 230000001363 autoimmune Effects 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 239000003638 chemical reducing agent Substances 0.000 description 4
• 230000004087 circulation Effects 0.000 description 4
• 230000002281 colonystimulating effect Effects 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 239000003246 corticosteroid Substances 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 208000010643 digestive system disease Diseases 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 239000007850 fluorescent dye Substances 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• 229960003180 glutathione Drugs 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 239000000710 homodimer Substances 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000000968 intestinal effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 210000004400 mucous membrane Anatomy 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 244000052769 pathogen Species 0.000 description 4
• 229920002704 polyhistidine Polymers 0.000 description 4
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• 230000001185 psoriatic effect Effects 0.000 description 4
• 230000009257 reactivity Effects 0.000 description 4
• 230000007115 recruitment Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 208000016261 weight loss Diseases 0.000 description 4
• 230000004580 weight loss Effects 0.000 description 4
• 206010048998 Acute phase reaction Diseases 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 241000193830 Bacillus <bacterium> Species 0.000 description 3
• 102100035882 Catalase Human genes 0.000 description 3
• 108010053835 Catalase Proteins 0.000 description 3
• 102000053642 Catalytic RNA Human genes 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
• 108010092408 Eosinophil Peroxidase Proteins 0.000 description 3
• 102100031939 Erythropoietin Human genes 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 108091029865 Exogenous DNA Proteins 0.000 description 3
• 208000018522 Gastrointestinal disease Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 108010052285 Membrane Proteins Proteins 0.000 description 3
• 208000034486 Multi-organ failure Diseases 0.000 description 3
• 208000010718 Multiple Organ Failure Diseases 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
• 238000000636 Northern blotting Methods 0.000 description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
• 102000057297 Pepsin A Human genes 0.000 description 3
• 108090000284 Pepsin A Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 206010037660 Pyrexia Diseases 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 230000006044 T cell activation Effects 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• 210000004100 adrenal gland Anatomy 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 239000007801 affinity label Substances 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 206010002022 amyloidosis Diseases 0.000 description 3
• 230000003042 antagnostic effect Effects 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 108010044715 asialofetuin Proteins 0.000 description 3
• 230000005784 autoimmunity Effects 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 238000009395 breeding Methods 0.000 description 3
• 230000001488 breeding effect Effects 0.000 description 3
• 238000004422 calculation algorithm Methods 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 238000000502 dialysis Methods 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 230000002327 eosinophilic effect Effects 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000002216 heart Anatomy 0.000 description 3
• 238000009396 hybridization Methods 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000009610 hypersensitivity Effects 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 239000002955 immunomodulating agent Substances 0.000 description 3
• 229960003444 immunosuppressant agent Drugs 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000004941 influx Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 238000004255 ion exchange chromatography Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 238000004020 luminiscence type Methods 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 210000003071 memory t lymphocyte Anatomy 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 3
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
• 230000003448 neutrophilic effect Effects 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 201000002528 pancreatic cancer Diseases 0.000 description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 description 3
• 229940111202 pepsin Drugs 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 210000001322 periplasm Anatomy 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 229910052698 phosphorus Inorganic materials 0.000 description 3
• 230000001817 pituitary effect Effects 0.000 description 3
• 229920002401 polyacrylamide Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000013615 primer Substances 0.000 description 3
• 210000000664 rectum Anatomy 0.000 description 3
• 108091092562 ribozyme Proteins 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 230000036269 ulceration Effects 0.000 description 3
• 241001529453 unidentified herpesvirus Species 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
• DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
• FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 2
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
• XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
• 102400000269 Amyloid protein A Human genes 0.000 description 2
• 101710144835 Amyloid protein A Proteins 0.000 description 2
• 208000012657 Atopic disease Diseases 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 101150029662 E1 gene Proteins 0.000 description 2
• 102100031780 Endonuclease Human genes 0.000 description 2
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
• 102100036509 Erythropoietin receptor Human genes 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• 108010067193 Formaldehyde transketolase Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 206010019695 Hepatic neoplasm Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 102100039064 Interleukin-3 Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 206010029379 Neutrophilia Diseases 0.000 description 2
• 108020004485 Nonsense Codon Proteins 0.000 description 2
• 108091060545 Nonsense suppressor Proteins 0.000 description 2
• 102000016979 Other receptors Human genes 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 101100311240 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) STF1 gene Proteins 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 206010041660 Splenomegaly Diseases 0.000 description 2
• 102100027780 Splicing factor, proline- and glutamine-rich Human genes 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 230000035508 accumulation Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000036428 airway hyperreactivity Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000003282 alkyl amino group Chemical group 0.000 description 2
• 230000029936 alkylation Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000003367 anti-collagen effect Effects 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000000837 carbohydrate group Chemical group 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000013522 chelant Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 239000012501 chromatography medium Substances 0.000 description 2
• PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 229940095074 cyclic amp Drugs 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 229960002086 dextran Drugs 0.000 description 2
• 238000002050 diffraction method Methods 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
• 229960002986 dinoprostone Drugs 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 238000002003 electron diffraction Methods 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000012202 endocytosis Effects 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000000630 fibrocyte Anatomy 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 210000002683 foot Anatomy 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 208000024557 hepatobiliary disease Diseases 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000002650 immunosuppressive therapy Methods 0.000 description 2
• 229940073062 imuran Drugs 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 230000008991 intestinal motility Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 230000007803 itching Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000008263 liquid aerosol Substances 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 208000014018 liver neoplasm Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 206010028197 multiple epiphyseal dysplasia Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 210000003061 neural cell Anatomy 0.000 description 2
• 230000037434 nonsense mutation Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 210000003463 organelle Anatomy 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 230000000242 pagocytic effect Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 238000005222 photoaffinity labeling Methods 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000000392 pressure-controlled scanning calorimetry Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 230000008085 renal dysfunction Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 238000013391 scatchard analysis Methods 0.000 description 2
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 230000008054 signal transmission Effects 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 238000001542 size-exclusion chromatography Methods 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 206010040882 skin lesion Diseases 0.000 description 2
• 231100000444 skin lesion Toxicity 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 208000032575 susceptibility to 2 autoimmune disease Diseases 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000008409 synovial inflammation Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 230000009278 visceral effect Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• 229910052727 yttrium Inorganic materials 0.000 description 2
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• JQFLYFRHDIHZFZ-RXMQYKEDSA-N (2s)-3,3-dimethylpyrrolidine-2-carboxylic acid Chemical compound CC1(C)CCN[C@@H]1C(O)=O JQFLYFRHDIHZFZ-RXMQYKEDSA-N 0.000 description 1
• CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
• FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
• CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
• KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
• KBDIEUYACKKLIJ-UHFFFAOYSA-N 2-isocyanatoguanidine Chemical compound NC(=N)NN=C=O KBDIEUYACKKLIJ-UHFFFAOYSA-N 0.000 description 1
• SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical group [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 102100038776 ADP-ribosylation factor-related protein 1 Human genes 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 206010060921 Abdominal abscess Diseases 0.000 description 1
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• 241001290610 Abildgaardia Species 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 241001182632 Akko Species 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 102100036826 Aldehyde oxidase Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 208000031295 Animal disease Diseases 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010071155 Autoimmune arthritis Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
• 101710166261 B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 108700040077 Baculovirus p10 Proteins 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 206010051728 Bone erosion Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 208000005024 Castleman disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000016951 Chemokine CXCL2 Human genes 0.000 description 1
• 108010014414 Chemokine CXCL2 Proteins 0.000 description 1
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 108020004638 Circular DNA Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010013554 Diverticulum Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 206010013786 Dry skin Diseases 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010053070 Glutathione Disulfide Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
• 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
• 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 102100020948 Growth hormone receptor Human genes 0.000 description 1
• 108010030204 H-asparaginyl-arginyl-valyl-tyrosyl-isoleucyl-histyl-prolyl-phenylalanyl-histyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
• 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 101000809413 Homo sapiens ADP-ribosylation factor-related protein 1 Proteins 0.000 description 1
• 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
• 101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 1
• YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 102400001232 IL-8(6-77) Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 108010060231 Insect Proteins Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 206010023203 Joint destruction Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
• KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 108010047357 Luminescent Proteins Proteins 0.000 description 1
• 102000006830 Luminescent Proteins Human genes 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 108010038049 Mating Factor Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 101710094503 Metallothionein-1 Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101100243377 Mus musculus Pepd gene Proteins 0.000 description 1
• 102100030856 Myoglobin Human genes 0.000 description 1
• 108010062374 Myoglobin Proteins 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• 101800000135 N-terminal protein Proteins 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 241001181114 Neta Species 0.000 description 1
• 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101800001452 P1 proteinase Proteins 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 229920001734 PEG propionaldehyde Polymers 0.000 description 1
• 101150029183 PEP4 gene Proteins 0.000 description 1
• 101150058514 PTGES gene Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 208000005775 Parakeratosis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
• 108010053210 Phycocyanin Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000013544 Platelet disease Diseases 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 101710182846 Polyhedrin Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000012515 Protein kinase domains Human genes 0.000 description 1
• 108050002122 Protein kinase domains Proteins 0.000 description 1
• 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 102000014128 RANK Ligand Human genes 0.000 description 1
• 108010025832 RANK Ligand Proteins 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 101100437728 Rattus norvegicus Bloc1s2 gene Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038063 Rectal haemorrhage Diseases 0.000 description 1
• 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 101100352915 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ppb1 gene Proteins 0.000 description 1
• 241000555745 Sciuridae Species 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108700028909 Serum Amyloid A Proteins 0.000 description 1
• 102000054727 Serum Amyloid A Human genes 0.000 description 1
• 108010068542 Somatotropin Receptors Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000033809 Suppuration Diseases 0.000 description 1
• 108700005078 Synthetic Genes Proteins 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 201000001322 T cell deficiency Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
• 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
• 102100034196 Thrombopoietin receptor Human genes 0.000 description 1
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
• 102100029337 Thyrotropin receptor Human genes 0.000 description 1
• 108700009124 Transcription Initiation Site Proteins 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 206010048222 Xerosis Diseases 0.000 description 1
• 229920002494 Zein Polymers 0.000 description 1
• PCBMGUSDYHYVBQ-SOOFDHNKSA-N [4-amino-2-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-imidazol-5-yl]phosphonic acid Chemical compound P(=O)(O)(O)C=1N=C(NC1N)C1[C@H](O)[C@H](O)[C@H](O1)CO PCBMGUSDYHYVBQ-SOOFDHNKSA-N 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 238000005377 adsorption chromatography Methods 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 230000010085 airway hyperresponsiveness Effects 0.000 description 1
• 208000037883 airway inflammation Diseases 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 108010004469 allophycocyanin Proteins 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 229920001718 aryloxy-PEG Polymers 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000008236 biological pathway Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 230000004097 bone metabolism Effects 0.000 description 1
• WVMHLYQJPRXKLC-UHFFFAOYSA-N borane;n,n-dimethylmethanamine Chemical compound B.CN(C)C WVMHLYQJPRXKLC-UHFFFAOYSA-N 0.000 description 1
• 150000001639 boron compounds Chemical class 0.000 description 1
• RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 235000010633 broth Nutrition 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 238000002045 capillary electrochromatography Methods 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 208000015636 celiac disease-epilepsy-cerebral calcification syndrome Diseases 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 229920001429 chelating resin Polymers 0.000 description 1
• 238000010382 chemical cross-linking Methods 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 229940117229 cialis Drugs 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 229940047120 colony stimulating factors Drugs 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 229920006237 degradable polymer Polymers 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 230000037336 dry skin Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• UXOLDCOJRAMLTQ-UHFFFAOYSA-N ethyl 2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(Cl)=NO UXOLDCOJRAMLTQ-UHFFFAOYSA-N 0.000 description 1
• BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
• 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 102000054767 gene variant Human genes 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 108010046301 glucose peroxidase Proteins 0.000 description 1
• 229930182478 glucoside Natural products 0.000 description 1
• 150000008131 glucosides Chemical class 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 102000035122 glycosylated proteins Human genes 0.000 description 1
• 108091005608 glycosylated proteins Proteins 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 108010044853 histidine-rich proteins Proteins 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000007366 host health Effects 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 238000013383 initial experiment Methods 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 150000004001 inositols Chemical class 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 102000004114 interleukin 20 Human genes 0.000 description 1
• 108090000681 interleukin 20 Proteins 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 229940096397 interleukin-8 Drugs 0.000 description 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 238000011031 large-scale manufacturing process Methods 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229920001427 mPEG Polymers 0.000 description 1
• 229960003511 macrogol Drugs 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• SKEFKEOTNIPLCQ-LWIQTABASA-N mating hormone Chemical compound C([C@@H](C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCS(C)=O)C(=O)NC(CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CN=CN1 SKEFKEOTNIPLCQ-LWIQTABASA-N 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
• 229960002329 methacholine Drugs 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 230000037125 natural defense Effects 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000001703 neuroimmune Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
• 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920002959 polymer blend Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000002987 primer (paints) Substances 0.000 description 1
• 230000002206 pro-fibrotic effect Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 201000010727 rectal prolapse Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 235000002020 sage Nutrition 0.000 description 1
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000010845 search algorithm Methods 0.000 description 1
• JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 108091005475 signaling receptors Proteins 0.000 description 1
• 230000037432 silent mutation Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 239000002689 soil Substances 0.000 description 1
• 238000003836 solid-state method Methods 0.000 description 1
• 229940033331 soy sterol Drugs 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 208000025889 stromal keratitis Diseases 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
• NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000019432 tissue death Effects 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 210000005092 tracheal tissue Anatomy 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229920001733 tresyl monomethoxy PEG Polymers 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000005019 zein Substances 0.000 description 1
• 229940093612 zein Drugs 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1